Armata Pharmaceuticals (ARMP) Depreciation & Amortization (CF) (2013 - 2026)

Armata Pharmaceuticals has disclosed Depreciation & Amortization (CF) across 14 years of filings, most recently posting $457000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $457000.0, up 21.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (up 17.26% YoY), and the FY2025 annual result was $1.5 million, up 15.55% from the prior year.
• Depreciation & Amortization (CF) came in at $457000.0 for Q1 2026 at Armata Pharmaceuticals, up from $431000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $457000.0 in Q1 2026 to a low of $200000.0 in Q2 2022.
• The 5-year median for Depreciation & Amortization (CF) is $313000.0 (2024), against an average of $304058.8.
• Across the five-year window, Depreciation & Amortization (CF) plunged 33.33% in 2022 and soared 41.63% in 2024, its largest moves.
• Armata Pharmaceuticals' Depreciation & Amortization (CF) stood at $245000.0 in 2022, then climbed by 19.59% to $293000.0 in 2023, then increased by 29.69% to $380000.0 in 2024, then rose by 13.42% to $431000.0 in 2025, then gained by 6.03% to $457000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $457000.0 (Q1 2026), $431000.0 (Q4 2025), and $370000.0 (Q3 2025), per Business Quant data.